Brian Anderson, MD

Education

Honors & Awards

• Academic Scholarship Award, UCSF Department of Psychiatry, 2018
• Krevans Award for Patient Care, SFGH, 2015
• Annual Student Paper Prize, Society for Medical Anthropology ADTSG, 2011

Selected Publications

1. Montoy JCC, Wang RC, Coker AR, Anderson BT. Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health. Drug Alcohol Depend. 2026 05 01; 282:113059. View on PubMed
2. Magar V, Robbins M, Fernández Lobo Blanco ÓML, Ali IL, Anderson B, Grob C, Henningfield JE, Kryskow P, Kuiper H, Loizaga-Velder A, Rush B, Volat M, Iron Rope S. Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration. J Psychopharmacol. 2026 Jan; 40(1):179-188. View on PubMed
3. Mian MN, Coker AR, Kretzer G, Cavnar C, Mitchell JM, Anderson BT. Investigating Safety Concerns and Harm Reduction in Entheogenic Churches: The Case for Community-Based Participatory Research. Curr Top Behav Neurosci. 2026; 77:513-529. View on PubMed
4. Mehtani NJ, Mian MN, Agin-Liebes G, Coker AR, Huebner C, Anderson BT, Mitchell JM. Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders. J Psychoactive Drugs. 2025 Nov 10; 1-10. View on PubMed
5. Alexander WB, Hansen ED, Anderson BT, Zarrabi AJ, Rogers AH, Loewen G, Ficarro ZR, Alexander MH, Schaefer D, Case AA. Meaning and Psychedelics in Palliative Care: A Narrative Review. J Pain Symptom Manage. 2026 Mar; 71(3):e299-e321. View on PubMed
6. Montoy JCC, Wang RC, Coker AR, Smollin CG, Anderson BT. US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022. J Am Coll Emerg Physicians Open. 2025 Oct; 6(5):100231. View on PubMed
7. Mehtani NJ, Anderson BT, Alexander I, Hendricks PS, Mitchell JM, Coffin PO, Johnson MO. Ketamine-Assisted Recovery (KARE): protocol for an open-label pilot trial of ketamine-assisted psychotherapy for publicly insured patients with methamphetamine use disorder and HIV risks. BMJ Open. 2025 Aug 24; 15(8):e100775. View on PubMed
8. Meacham MC, Mian MN, Wang RC, Coker AR, Anderson BT, Montoy JCC. Latent Classes of Lifetime Use of Seven Hallucinogens in the United States. J Psychoactive Drugs. 2025 Aug 04; 1-7. View on PubMed
9. Passie T, Loizaga-Velder A, Danforth A, Grob CS, Greer GR, Erritzoe D, Oehen P, Styk J, Schlichting M, Vermetten E, Goksøyr IW, Palenicek T, Mithoefer MC, Mithoefer A, Anderson B, Krediet E, Gasser P, Nielson EM, Gorman I, Phelps J, Belser AB, Guss J. A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy. J Psychopharmacol. 2026 Jan; 40(1):98-109. View on PubMed
10. Grossman DH, Madden KM, Mehtani NJ, Anderson BT, Davis LL, Mitchell JM, Hendricks PS. A systematic review of income and education reporting in psychedelic clinical trials. Nat Ment Health. 2025 May; 3(5):567-574. View on PubMed
11. Evans J, Aixalà M, Anderson BT, Brennan W, Bremler R, Breeksema JJ, Burback L, Calder AE, Carhart-Harris RL, Cheung K, Devenot N, Gorman I, Gren J, Hendricks PS, Holoyda B, Jacobs E, Krecké J, Kruger DJ, Luke D, Majic T, McGuire AL, Mehtani NJ, Mathai DS, Nash K, Noorani T, Palitsky R, Robinson OC, Simonsson O, Stahre E, van Elk M, Yaden DB. On Minimizing Risk and Harm in the Use of Psychedelics. Psychiatr Res Clin Pract. 2025; 7(1):4-8. View on PubMed
12. Mian MN, Dinh MT, Coker AR, Mitchell JM, Anderson BT. Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options. Am J Psychiatry. 2025 Jan 01; 182(1):6-9. View on PubMed
13. Dinh MT, Bell B, Bourgeois JA, Weaver E, Martin J, O'Riordan DL, Rabow M, Kaplan L, Anderson B. Implementation of the California End of Life Option Act at UCSF: Examining the Utility of the Mandatory Mental Health Assessment in Medical Aid in Dying. J Acad Consult Liaison Psychiatry. 2025 Mar-Apr; 66(2):172-178. View on PubMed
14. Mehtani NJ, Johnson MO, Hendricks PS, Mitchell J, Anderson BT. Psilocybin-assisted therapy and HIV-related shame. Sci Rep. 2024 08 02; 14(1):17919. View on PubMed
15. Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y. Older adults in psychedelic-assisted therapy trials: A systematic review. J Psychopharmacol. 2024 Jan; 38(1):33-48. View on PubMed
16. Mehtani NJ, Anderson BT, Mitchell JM. Psychedelics in Addiction Treatment-Navigating a Sociopolitical Rift. JAMA Neurol. 2024 Jan 16. View on PubMed
17. O'Donnell KC, Anderson BT, Barrett FS, Bogenschutz MP, Grob CS, Hendricks PS, Kelmendi B, Nayak SM, Nicholas CR, Paleos CA, Stauffer CS, Gukasyan N. Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy. Am J Psychiatry. 2024 01 01; 181(1):74-75. View on PubMed
18. Magar V, Urrutia J, Anderson BT. Psychedelic Research and Therapeutic Practices: Embracing Communities, Groups, and Traditional Knowledge. J Psychoactive Drugs. 2023 Nov-Dec; 55(5):519-522. View on PubMed
19. Urrutia J, Anderson BT, Belouin SJ, Berger A, Griffiths RR, Grob CS, Henningfield JE, Labate BC, Maier LJ, Maternowska MC, Weichold F, Yaden DB, Magar V. Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health. J Psychoactive Drugs. 2023 Nov-Dec; 55(5):523-538. View on PubMed
20. Mitchell JM, Anderson BT. Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology. 2024 01; 49(1):96-103. View on PubMed

Go to UCSF Profiles, powered by CTSI